Global Cardiovascular and Renal Outcomes of Reduced GFR

ABSTRACT
The burden of premature death and health loss from ESRD is well described. Less is known regarding the burden of cardiovascular disease attributable to reduced GFR. We estimated the prevalence of reduced GFR categories 3, 4, and 5 (not on RRT) for 188 countries at six time points from 1990 to 2013. Relative risks of cardiovascular outcomes by three categories of reduced GFR were calculated by pooled random effects meta-analysis. Results are presented as deaths for outcomes of cardiovascular disease and ESRD and as disability-adjusted life years for outcomes of cardiovascular disease, GFR categories 3, 4, and 5, and ESRD. In 2013, reduced GFR was associated with 4% of deaths worldwide, or 2.2 million deaths (95% uncertainty interval [95% UI], 2.0 to 2.4 million). More than half of these attributable deaths were cardiovascular deaths (1.2 million; 95% UI, 1.1 to 1.4 million), whereas 0.96 million (95% UI, 0.81 to 1.0 million) were ESRD-related deaths. Compared with metabolic risk factors, reduced GFR ranked below high systolic BP, high body mass index, and high fasting plasma glucose, and similarly with high total cholesterol as a risk factor for disability-adjusted life years in both developed and developing world regions. In conclusion, by 2013, cardiovascular deaths attributed to reduced GFR outnumbered ESRD deaths throughout the world. Studies are needed to evaluate the benefit of early detection of CKD and treatment to decrease these deaths.
Understanding the true societal effect of CKD requires evaluating the independent burdens of ESRD and reduced GFR–associated CV disease. Such data would guide national priorities regarding the benefit of early CKD detection. Early CKD detection and management could defray costs related to eventual ESRD development and higher likelihood of CV disease.

**Figure 1.** Higher burden of GFR-attributable deaths and disability-adjusted life years (DALYs) by world region in 2013. (A) Age-standardized deaths per 100,000 in 2013 attributed to reduced GFR. (B) Age-standardized DALYs per 100,000 in 2013 attributed to reduced GFR.
disease development. Thus, we aim to determine the burden of CV disease because of reduced GFR among 188 countries, compare this to the ESRD burden, and evaluate how this combined burden ranks among leading causes of health loss and premature death.

RESULTS

Global Reduced-GFR Mortality and Disability adjusted life-years in 2013

In 2013, 2.2 million deaths were associated with reduced GFR (Figure 1A, Table 1). Nearly 52 million disability-adjusted life years (DALYs) were associated with reduced GFR (Figure 1B, Table 1). These attributable deaths and DALYs account for 3.9% of total global deaths and 2.1% of total global DALYs in 2013, respectively (Table 1).

Changes in Reduced GFR DALY Rates since 1990

At the global level, among all ages, GFR-attributable median DALY counts have increased by 52.0%, respectively, whereas age-standardized rates of DALYs associated with reduced GFR have decreased by 8.1%, respectively (Supplemental Table 1, Tables 1 and 2). Compared with other metabolic risk factors, since 1990, among all ages, DALYs attributed to high fasting glucose (69.6%; 95% uncertainty interval [95% UI], 60.9 to 78.7), high total cholesterol (26.9%; 95% UI, 19.8 to 36.3), and high BP (49.1%; 95% UI, 43.2 to 55.2) have all increased (Supplemental Figure 1). Age-standardized DALY rates for the risk factors high BP (−16.5 mmHg; 95% UI, −20.0 to −12.5) and high total cholesterol (−27.5; 95% UI, −31.5 to −22.1) have decreased, whereas DALY rates associated with high fasting glucose have remained relatively constant (0.2%; 95% UI, −4.8 to 5.6).

Geographic Patterns for Reduced GFR Mortality in 2013

Among super-regions, reduced GFR ranked highest in Latin America and the Caribbean (fifth), with 7.0% of total attributed deaths and outranking metabolic risk factor high total cholesterol (seventh). Within the high-income super-region, reduced GFR ranked eighth and was outranked by all metabolic risk factors except for low bone mineral density (17th). Reduced GFR ranked lowest in sub-Saharan Africa (16th), but still outranked high total cholesterol (25th) with regards to deaths (Figures 2 and 3).

CV Disease Attributed to Reduced GFR

In 2013, globally there were 1.2 million CV deaths attributed to reduced GFR, with an age-standardized rate of 20.8 deaths per 100,000 (Table 2). Since 1990, reduced GFR–associated CV deaths have increased by 33.8% (95% UI, 24.6 to 43.8), whereas the age-standardized GFR-attributable rate has decreased by 28.6% (Table 2). The 2013 age-standardized CV mortality rate within the developing world (21.5 per 100,000) was slightly higher than in the developed world (19.2 per 100,000) (Table 2). Notably, the age-standardized CV mortality rate in the developing world has decreased slightly since 1990 (9.5% decline), whereas the developed world has demonstrated a 44% decline in age-standardized CV mortality (Table 2).

Reduced GFR was responsible for 18.7 million CV DALYs in 2013 among all ages, with an age-standardized rate of 304.2 DALYs per 100,000 (Figure 4, Table 3). The developing world had a higher rate, as well as a smaller decrease in rate since 1990, when compared with the developed world (Table 3). Among super-regions, the highest age-standardized GFR-attributed CV mortality rates were estimated for Central Europe, Eastern Europe, Central Asia, and sub-Saharan Africa (Table 2). Since 1990, GFR-attributed CV mortality rates in sub-Saharan Africa and South Asia tended to increase, as opposed to all other super-regions. The high-income super-region demonstrated the greatest decrease in mortality rate since 1990 (Table 2).

ESRD Deaths and CKD DALYs

Globally there were 956,246 (95% UI, 812,896 to 1,034,491) deaths because of ESRD in 2013, with an age-standardized rate of 15.8 per 100,000 (Table 2). Since 1990, both the number of deaths (134.6%; 95% UI, 115.7% to 150.2%) and age-standardized mortality rate (36.9%) have increased (Table 2). The age-standardized mortality rate in the developing world was almost twice that of the developed, and has increased by 44.7% since 1990, compared with the 9.8% increase within the developed world (Table 2).

The super-region with highest ESRD mortality rate in 2013 was Latin America and the Caribbean, with an ESRD mortality rate of 32 per 100,000, which is almost double the global rate (Table 2). South Asia demonstrated the greatest increase in CKD deaths (82.9%) since 1990, although all developing super-regions demonstrated an increase in ESRD mortality (Table 2).

Table 1. 2013 GFR-attributable deaths and DALY counts among all ages

<table>
<thead>
<tr>
<th>World Region</th>
<th>Mortality Counts (95% CI)</th>
<th>PAF% (95% CI)</th>
<th>DALYs Counts (95% CI)</th>
<th>PAF% (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Global</td>
<td>2,163,699 (1,959,711 to 2,387,042)</td>
<td>3.9 (3.6 to 4.3)</td>
<td>51,905,836 (46,245,898 to 57,573,443)</td>
<td>2.1 (1.9 to 2.3)</td>
</tr>
<tr>
<td>Developed</td>
<td>696,832 (615,822 to 797,400)</td>
<td>5.3 (4.7 to 6.1)</td>
<td>12,699,916 (11,026,556 to 14,497,193)</td>
<td>3.3 (2.9 to 3.7)</td>
</tr>
<tr>
<td>Developing</td>
<td>1,466,868 (1,256,422 to 1,633,677)</td>
<td>3.5 (3.0 to 3.9)</td>
<td>39,205,920 (33,942,972 to 43,716,898)</td>
<td>1.9 (1.7 to 2.1)</td>
</tr>
</tbody>
</table>

Data in parentheses indicate 95% uncertainty intervals.
At the global level, age-standardized CKD DALY rate have increased by 12.3%, but this increase largely occurred within the developing world (Table 3). In 2013, CKD DALY rates were highest in the Latin America and the Caribbean region (829 per 100,000), and lowest for Central Europe, Eastern Europe, Central Asia (398 per 100,000) and Southeast Asia, East Asia, and Oceania (393 per 100,000) (Figure 5, Table 3). Age-standardized rates have decreased in three world regions since 1990 (Central Europe, Eastern Europe, and Central Asia [−6.7%]; high-income [−0.7%]; and North Africa and Middle East [−3.1%]) (Table 3). The largest increases in age-standardized CKD DALY rates occurred in Latin America and the Caribbean (39.1%) and South Asia (39.6%), driving the notable increase in the CKD DALY rate within the developing world in comparison to the developed world.

**DISCUSSION**

The Global Burden of Disease (GBD) Study 2013 ranks reduced GFR as the 12th leading risk factor for CV and ESRD deaths at the global level, and the 14th leading risk factor for DALYs among 79 risk factors in 2013.17 Within world regions such as high-income and Latin America and the Caribbean, the mortality rating was as high as eighth and fifth, respectively. This analysis provides granular detail regarding the contribution of CV disease caused by reduced GFR to these rankings. In 2013, 2.2 million deaths and 52 million DALYs were associated with reduced GFR. More than half of attributable deaths were estimated to have occurred secondary to CV disease.

The GBD Study indicates that in 1990, the developed world demonstrated notably higher rates of total CV disease among all ages than in developing world regions. Over time, the burden of age-standardized fatal CV disease has markedly declined in the developed world, whereas it has largely remained stable within developing regions.18 These shifting patterns of total CV disease activity in the developed and developing worlds are driving the overall pattern of GFR-attributable CV DALY and death activity. There are likely three factors contributing to the change in prevalence of total CV disease within the developing world. First, improved success in treating leading causes of premature mortality within resource-limited nations, mainly related to infectious diseases and maternal–perinatal mortality, has allowed individuals to reach more advanced age and thus develop conditions related to aging.18–20 Second, the shift in diet toward greater intake of animal fat and high-caloric food has been documented within the developing world for at least the past decade, facilitating CV disease development. Third, limited implementation of CV risk factor detection, treatment, and disease management within the developing world in the setting of a growing burden has led to sustained mortality rates.18,20,21 The differences between age-standardized and all age rates merit further research.

Our results showing the attributable CV burden within the developing world may illustrate the success within regions such

---

**Table 2. GFR and CKD mortality attributable to reduced GFR in 2013**

<table>
<thead>
<tr>
<th>World Region</th>
<th>GFR-Attributable Counts among All Ages</th>
<th>GFR-Attributable Rate per 100,000</th>
<th>% Change in GFR-Attributable Counts since 1990</th>
<th>AS GFR-Attributable Rate per 100,000</th>
<th>% Change in GFR-Attributable Rates since 1990</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Global</strong></td>
<td>1,207,453 (1,049,528 to 1,400,049)</td>
<td>20.8 (18.1 to 24.1)</td>
<td>−9.6 (−32.9 to −2.1)</td>
<td>28.6 (23.9 to 32.9)</td>
<td>16.7 (−2.5 to 37.8)</td>
</tr>
<tr>
<td><strong>Developed</strong></td>
<td>465,696 (389,760 to 544,138)</td>
<td>19.2 (16.2 to 22.2)</td>
<td>−8.5 (−16.0 to −3.9)</td>
<td>231,135 (202,554 to 263,899)</td>
<td>9.8 (−12.1 to 22.2)</td>
</tr>
<tr>
<td><strong>Developing</strong></td>
<td>741,757 (629,223 to 884,731)</td>
<td>21.5 (18.0 to 25.5)</td>
<td>−9.5 (−16.0 to −4.0)</td>
<td>725,111 (597,781 to 874,578)</td>
<td>10.7 (−12.1 to 27.0)</td>
</tr>
<tr>
<td><strong>High-income</strong></td>
<td>256,696 (207,834 to 310,883)</td>
<td>12.6 (10.3 to 15.2)</td>
<td>−5.0 (−10.3 to −5.0)</td>
<td>221,577 (192,402 to 271,454)</td>
<td>10.4 (−12.1 to 27.0)</td>
</tr>
<tr>
<td><strong>Low-income</strong></td>
<td>99,368 (84,266 to 116,727)</td>
<td>39.1 (32.4 to 45.6)</td>
<td>0.4 (−7.4 to 7.9)</td>
<td>55,226 (49,104 to 62,712)</td>
<td>0.7 (−7.4 to 7.9)</td>
</tr>
<tr>
<td><strong>Central Europe</strong></td>
<td>299,425 (258,172 to 361,441)</td>
<td>44.1 (37.7 to 51.8)</td>
<td>−28.7 (−33.8 to −23.4)</td>
<td>68,796 (59,131 to 78,491)</td>
<td>−28.7 (−33.8 to −23.4)</td>
</tr>
<tr>
<td><strong>Sub-Saharan Africa</strong></td>
<td>235,330 (176,700 to 305,149)</td>
<td>28.3 (20.9 to 35.6)</td>
<td>−7.5 (−11.8 to −2.2)</td>
<td>191,333 (123,002 to 258,208)</td>
<td>−7.5 (−11.8 to −2.2)</td>
</tr>
<tr>
<td><strong>Middle East</strong></td>
<td>235,885 (186,927 to 294,441)</td>
<td>23.9 (18.9 to 27.5)</td>
<td>−7.5 (−11.8 to −2.2)</td>
<td>235,885 (186,927 to 294,441)</td>
<td>−7.5 (−11.8 to −2.2)</td>
</tr>
<tr>
<td><strong>Latin America and Caribbean</strong></td>
<td>92,531 (73,600 to 114,393)</td>
<td>23.9 (18.9 to 27.5)</td>
<td>−7.5 (−11.8 to −2.2)</td>
<td>92,531 (73,600 to 114,393)</td>
<td>−7.5 (−11.8 to −2.2)</td>
</tr>
</tbody>
</table>

Data in parentheses indicate 95% uncertainty intervals. Super-regions are comprised of the following regions: High-income: Asia Pacific, Australasia, Western Europe, Southern Latin America, North America; Saharan Africa; North Africa and Middle East: North Africa, Middle East; South Asia: South Asia; Southeast Asia, East Asia; and Oceania: East Asia, Southeast Asia, Oceania. AS, age-standardized.
as North America and Western Europe in addressing risk factors for incident CV disease over the past decades. Importantly, when comparing the reduced GFR risk factor to other CV risk factors, such as high blood glucose, high BP, elevated total cholesterol, and smoking, reduced GFR and elevated fasting glucose had the lowest decrease in DALY rates within the past two decades. This finding suggests that building on the success of CV risk factor detection and treatment will require paying equal attention to more novel CV risk factors, such as reduced GFR, in the coming years, as well as their treatments.

Regarding ESRD deaths and CKD DALYs, recent meta-analyses have estimated >2 million individuals to have died prematurely in 2010 because of lack of access to dialysis, and that the majority of these deaths occurred within Southeast Asia and Africa. Similar to these estimates, our results indicate a high burden of CKD DALYs to have occurred in sub-Saharan Africa, but our results also highlight the very high burden of CKD DALYs in Mexico, most likely related to their extraordinarily high rate of diabetes mellitus. Despite high death rates to ESRD within world regions with no ESRD care access, the literature also describes the encouraging statistic of growth in dialysis provision over the past two decades. Studies indicate that this growth relates more to government expansion of dialysis programs rather than the increase in causative diseases of ESRD, such as diabetes and hypertension. Considering this, attention needs to be paid to ESRD prevention strategies alongside continued development of ESRD programs.

The potential public health benefits of CKD screening have been evaluated in the past. Cost-effectiveness CKD screening studies that fully incorporated fatal and nonfatal CV outcomes as well as incident ESRD have concluded CKD screening within the general population to be cost-effective, in opposition to results of studies that only incorporated ESRD outcomes and fatal CV disease. These results are the first to quantify and compare ESRD and reduced GFR attributable CV outcomes across developed and developing nations, and illustrate that ESRD represents less than half of health events attributable to reduced GFR, even within the developing world. This reiterates the importance of CV fatal and nonfatal disease incorporation into evaluations of the health and economic benefits of population CKD screening. Within low- and middle-income countries, it is possible that CKD screening is of even higher importance in forestalling ESRD development, because RRT is limited in more than half of the world’s countries.

Evidence exists from randomized controlled trials of the benefit of statins in lowering CV morbidity. A recent major meta-analysis described that intensive BP control tended to reduce the relative risk of some CV outcomes, although not CV mortality or ESRD development. There is need for similar evidence demonstrating that diagnosing CKD early and slowing CKD progression lowers CV disease incidence and mortality. There are strong arguments that population-level CKD screening using urinary albumin and GFR measurement could potentially complement screening for hypertension and
diabetes, the treatment of which would forestall CKD progression.33–35

In developing countries, access to care is a barrier to chronic disease detection and treatment.26 Literature suggests that the prevalence of undiagnosed hypertension and diabetes is higher in developing than developed nations.26 Yet there are examples of efforts to detect and treat chronic diseases even within resource-limited settings. A non-profit organization within Cambodia uses a community health worker approach to screen rural Cambodian adults for diabetes, hypertension, obesity, and CKD, and initiates treatment for these conditions, paired with diet and lifestyle modification and strict follow-up.38 Results from this organization indicate very favorable control of diabetes mellitus, hypertension, and CKD progression.39 Similar results have been published for chronic disease outreach programs in the Philippines and the Democratic Republic of Congo.40 Such screening and management interventions illustrate the importance and feasibility of chronic disease detection and management to delay progression, even in remote settings.

Within the developed region, although CKD DALY rates have decreased slightly since 1990, mortality rates have not, which could be explained in part by increasing age at death. This is in notable contrast to the almost 45% reduction over that time period in CV disease deaths associated with reduced GFR within the developed world. Success in addressing this CKD burden will likely involve continued efforts at early diagnosis and treatment of hypertension, diabetes mellitus, and early-stage CKD. These measures will also be necessary within developing nations, coupled with infrastructure development for treatment of ESRD.31,32

Within certain regions, unique contributors to ESRD development require focused attention by that nation’s health care infrastructure. This concerns not only diabetes mellitus, hypertension, HIV, and other well known factors leading to kidney damage, but also the CKDu, the latter studied recently mainly in specific Latin American and Southeast Asian countries,41–45 with several hypothesized causes, including environmental exposures, toxins, and climate change. To date, there is no clear leading etiological factor.36 CKDu often targets young men to a higher degree than CKD caused by known factors, and is now considered endemic in countries such as Sri Lanka, India, El Salvador, and Nicaragua, and is the leading cause of hospital deaths in El Salvador.36,37 The challenges surrounding the CKDu epidemic exemplify how methods for detecting and addressing CKD burden may have to extend beyond screening for traditional CKD risk factors within classically defined high-risk portions of the population, in order to prevent ESRD deaths and CKD DALYs.

Making global estimates inherently requires assumptions and has limitations. First, CKD prevalence data were only available for 44 countries; among 1000 surveys, methods were often not optimal; and within most countries, not all time points were included. The Bayesian methods provide the best estimates possible but are limited by the quality of the available data. Furthermore, inconsistency of data collection of time and world region could influence trends and geographic variation. An area for improvement of this analysis would involve incorporating albuminuria into the exposure definition for the population-attributable fractions (PAF) calculation; there is strong evidence in the literature demonstrating the independent association between albuminuria and CV events, in isolation of and in addition to reduced GFR.46 Thus, the estimates that we present might possibly underestimate the true burden of CV events associated with CKD. These limitations serve as steps for improvement of future estimations.
A significant strength of this study involves the relative risk determination for incident CV events by stage of kidney dysfunction in a global consortium. Further strengths involve our ability to estimate fatal and nonfatal burden for specific CV diseases as well as ESRD throughout the world and across time.

Reduced GFR-attributable CV deaths outnumber ESRD deaths at the global level, and the death rate from ESRD is increasing throughout the world and is a leading cause of death in world regions such as Latin America and the Caribbean. Efforts to forestall such rates will involve earlier detection of CKD. Affordable means of detecting early-stage CKD are available, as well as affordable means of treating early-stage CKD to delay progression.47 In order to evaluate whether such screening methods should be recommended for the general population, further cost-effectiveness analyses will need to be conducted that incorporate the 1.2 million reduced GFR-attributable CV disease deaths. It will be difficult to alter death rates within the CKD population without such studies and screening efforts.

**CONCISE METHODS**

**Study Overview**
This analysis follows the risk assessment framework used in the 2013 GBD Study for 79 individual and combined risk factors, where prevalence of the exposure is determined, a theoretical minimum risk is defined, and the relative risk of a causally-related health outcome is quantified (Supplemental Appendix 1, Supplemental Table 3).17,48

**PAFs**
We calculated the CV fatal and nonfatal burden attributable to the categorical exposure of reduced GFR categories using the following equation:

\[
PAF = \frac{\sum_{i=1}^{n} P_i (RR_i - 1)}{\sum_{i=1}^{n} P_i (RR_i - 1) + 1}
\]

where \(RR_i\) is the relative risk for exposure level \(i\), \(P_i\) is the proportion of the population in that exposure category, and \(n\) is the number of exposure categories.49

**Exposure**
An overview of the modeling method used for determining country-level prevalence of GFR categories <15 ml/min per 1.73 m² (not on dialysis), 15–29 ml/min per 1.73 m², and 30–59 ml/min per 1.73 m² is provided in Supplemental Appendices 2 and 5. We used these country-level prevalence estimates of reduced GFR categories as our exposure categories (Supplemental Tables 4–6).
Table 3. CV and CKD DALYs attributable to reduced GFR in 2013

| Region          | CV Disease | CKD Prognosis Consortium (14 cohorts, n=135,484) with estimated kidney function on the basis of serum creatinine and prospective assessment of fatal and nonfatal CV events (Supplemental Table 2). The relative risk for peripheral vascular disease by stage of reduced renal function was determined from the Atherosclerotic Risk in the Communities cohort. We attributed 100% of ESRD incidence and mortality to reduced GFR (details provided in Supplemental Appendix 3, Relative Risk Determination).

Outcomes

CV outcomes of ischemic heart disease, stroke, as well as peripheral vascular disease, ESRD deaths, and CKD DALYs at the country, age, sex, and year level were obtained from the 2013 GBD Study (Supplemental Appendix 4).

World Regions

The countries of which regions and super-regions are comprised are listed in Supplemental Table 1.

ACKNOWLEDGMENTS

The authors thank the staff and participants of the Atherosclerosis Risk in Communities (ARIC) Study for their important contributions. The authors thank the other investigators, the staff, and the participants of the Multi-Ethnic Study of Atherosclerosis (MESA) for their valuable contributions. Dade Behring (Marburg, Germany) supplied equipment and reagents for nephelometric measurement of urinary albumin. The authors thank the other investigators, the staff, and the patients of the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study for their valuable contributions. The authors thank the doctors, nurses, students, volunteers, and organizations involved in country screening programs which made collection of data for the International Society of Nephrology–Kidney Disease Data Center (ISN-KDDC) Study possible.

The ARIC study is carried out as a collaborative study supported by the National Heart, Lung, and Blood Institute (NHLBI; contracts HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C). The Australian Diabetes, Obesity and Lifestyle Study is supported by the Baker IDI Heart and Diabetes Institute, Melbourne, Australia, their sponsors, and the National Health and Medical Research Council of Australia (grant 233200), Amgen Australia, Kidney Health Australia, and The Royal Prince Alfred Hospital, Sydney, Australia. Beaver Dam is supported by the National Institutes of Health (NIH) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grants NIH/NIDDK DK7321 and NIH/NEI T32 EY 06594, and an unrestricted grant from Research to Prevent Blindness. The Epidemiological investigations on chronic diseases in an elderly population study is supported by the Ministry of Research, Science and the Arts Baden-Württemberg (Stuttgart, Germany), Federal Ministry of Education and Research (Berlin, Germany), Federal Ministry of Family Affairs, Senior Citizens,
Women and Youth (Berlin, Germany), and the European Commission FP7 framework programme of DG-Research (Consortium on Health and Ageing: Network of Cohorts in Europe and the United States Project). Measurement of urinary albumin was funded by Dade-Behring, Marburg, Germany. Boris Bikbov has received funding from the European Union Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement no. 703226. The NHLBI Framingham Heart Study is supported by grant N01-HC-25195. The Global Burden of Disease Study is supported by the Bill and Melinda Gates Foundation. The MESA study is supported by contracts N01-HC-95159 to N01-HC-95169 from the NHLBI and by grants UL1-RR-000040 and UL1-RR-025005 from National Center for Research Resources. The Ohasama Study is supported by grants-in-aid (H20-22Junkankitou [Seishuu]-Ippan-009, 013 and H23-Junkankitou [Senshu]-Ippan-005) from the Ministry of Health, Labor and Welfare, Health and Labor Sciences Research Grants, Japan, and the Japan Atherosclerosis Prevention Fund. The Uppsala Longitudinal Study of Adult Men is supported by the Swedish Research Council, the Swedish Heart-Lung Foundation, the Marianne and Marcus Wallenberg Foundation, Dalarna University, and Uppsala University. The Prevention of Renal and Vascular End-stage Disease Study is supported by several grants from the Dutch Kidney Foundation, and grants from the Dutch Heart Foundation, the Dutch Government, the NIH, and the University Medical Center Groningen, The Netherlands. The REGARDS research project is supported by a cooperative agreement (U01 NS041588) from the National Institute of Neurological Disorders and Stroke, NIH, Department of Health and Human Service. Additional funding was provided by an investigator-initiated grant-in-aid from Amgen and an investigator-initiated NHLBI grant (R01 HL080477). The Severance Study is supported by the Seoul City R&D program (10526), Korea, the National R&D Program for Cancer Control, Ministry for Health, Welfare and Family Affairs, Republic of Korea (1220180), and the National Research Foundation of Korea grant funded by the Korean Government (2011-0029348). The Gubbio Study is supported by the Municipal and Health Authorities of Gubbio, Italy; the Federico II University, Naples, Italy; University of Milan, Milan, Italy; Istituto Superiore di Sanità, Rome, Italy; Northwestern University, Chicago; University of Salerno, Italy; and Merck Sharp & Dohme, Italy. The ISN-KDDC study is supported by the International Society of Nephrology, Research and Prevention Committee, Brussels, Belgium and the Istituto di Ricerche Farmacologiche Mario Negri, Clinical Research Center for Rare Diseases Aldo e Cele Daccò, Bergamo, Italy. The Rancho Bernardo Study is supported by grants National Institute on Aging AG07181 and AG028507 NIDDK DK31801.

These results do not reflect the views of The Bill and Melinda Gates Foundation. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Neurological Disorders and Stroke or the NIH. Representatives of the National Institute of Neurological Disorders and Stroke, NIH, Department of Health and Human Service have been involved in the review of the manuscript but not directly involved in the collection, management, analysis, or interpretation of the data. Representatives from Amgen and NHLBI did not have any role in the design and conduct of the...
study, the collection, management, analysis, and interpretation of the data, or the preparation or approval of the manuscript.

A full list of participating MESA investigators and institutions can be found at http://www.mesa-nhlbi.org. A full list of participating REGARDS investigators and institutions can be found at http://www.regardsstudy.org.

DISCLOSURES
None.

REFERENCES


Bemadette Thomas,* Kunihiro Matsushita,1 Kalkidan Hassen Abate,5 Ziyad Al-Aly,1 Johan Ämlö,5 Kei Asayama,1 Robert Atkins,12 Alaa Badawi,6,7 Shoshana H. Ballew,1 Amitava Banerjee,10 Lars Barregärd,8,9 Elizabeth Barrett-Conner,9 Sanjay Basu,6 Aminu K. Bello,5 Isabel Bensenor,6 Jaclyn Bergstrom,11 Boris Bikbov,6 JChristopher Blosser; Hermann Brenner,11 Juan-Jesus Carrero,12 Steve Chadbourn,5,9,10 Massimo Cinillo,6,7,11 Monica Cortinovis,11,12 Karen Courville,11,12 Lalit Dandona,4,12 Rahki Dandona,4,12 Kara Estep,4 João Fernandes,6,7,11 Florian Fischer,4,12 Caroline Fox,5,10 Ron T. Garseauoon,5,11 Philipmon N. Gona,11,12 Orlando M. Gutiérrez,11,12 Samer Hamidi,5,9,10 Sarah Wulf Hanson,4 Jonathan Himmelfarb,5 Smerjot K. Jassal,11,12 Sun Ha Jee,5,9 Vivekanand Jha,5,9,10 Aida Jimenez-Corona,5,9,10,12 Jost B. Jonas,11 Andre Pascal Kengne,6,7,11 Yousef Khader,5,9,10 Young-Ho Khang,4,12 Yun Jin Kim,5,9,10 Barbara Klein,6,7,11 Ronald Klein,6,7 Yoshiiro Kubo,5,10 Dhaval Kolte,5,11 Kristine Lee,4,12 Andrew S. Levey,5,9,10,12 Yongmei Li,5,9,10,12 Paulo Lotufo,5,10 Hassan Magdy Abd El Razek,11,12 Walter Mendoza,5,9,10 Hirohito Metoki,4,10 Yejin Mok,5,9,10 Isao Muraki,5,9,10 Paul M. Muntner,5,10,11 Noberto Perico,5,10 Kevan Polkinghome,5,9,10 Raja Al-Radadi,5,9,10 Giuseppe Remuzzi,5,9,10,11 Gregory Roth,5,9,10 Dietrich Rothenbacher,5,9,10 Michihiro Satoh,5,9,10 Kai-Uwe Saum,5,9,10 Monika Sawhney,5,9,10 Ben Schöttker,5,9,10 Anoop Shankar,5,9,10 Michael Shlipak,5,9,10 Diego Augusto Santos Silva,5,9,10 Hideaki Toyoshima,5,9,10 Kingsley Ukwaja,5,9,10,11 Mitsumasa Umesawa,5,9,10,11 Stein Emil Vollset,*5,9,10,11†5,9,10 David G. Warnock,5,9,10,11 Andrea Werdecker,5,9,10 Kazumasa Yamagishi,5,9,10 Yuichiro Yano,5,9,10 Na Hiroshi Yokota,5,9,10 Maysaa El Sayed Zaki,5,9,10 Mohsen Naghavi,* Mohammad H. Forouzanfar,* Christopher J.L. Murray,* Josep Coresh,* Theo Vos,* on behalf of the Global Burden of Disease 2013 GFR Collaborators, CKD Prognosis Consortium, and Global Burden of Disease Genitourinary Expert Group

*Institute for Health Metrics and Evaluation, 1Internal Medicine, Nephrology, University of Washington, Seattle, Washington; 2Department of Epidemiology and Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland; 3Jimma University, Jimma, Ethiopia; 4Washington University in St. Louis, St. Louis, Missouri; 5Division of Family Medicine and Primary Care, Department of Neurobiology, Care Science and Society, Karolinska Institutet, Huddinge, Sweden; 6School of Health and Social Studies, Dalarna University, Falun, Sweden; 7Teikyo University School of Medicine, Tokyo, Japan; 8Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia; 9Public Health Agency of Canada, Toronto, Ontario, Canada; 10Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; 11Farr Institute of Health Informatics Research, University College London, London, England, United Kingdom; 12Department of Family Medicine and Public Health, 13Veterans Affairs, University of California, San Diego, San Diego, California; 14Stanford University, Stanford, California; 15Department of Medicine, University of Alberta, Edmonton, Alberta, Canada; 16University of São Paulo, São Paulo, Brazil; 17Department of Nephrology and Transplanted Kidney, Academyiic V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow, Russia; 18Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany; 19Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden; 20Australia and New Zealand Dialysis and Transplant Registry, Adelaide, South Australia; 21Sydney School of Public Health, University of Sydney, New South Wales, Australia; 22Renal Medicine, Royal Prince Alfred Hospital, New South Wales, Australia; 23University of Salerno, Baronissi, Italy; 24Istituto Di Ricerco e CurA Carattere Scientifico, Istituto di Ricerche Farmacologiche Mario Negri, Bergamo, Italy; 25Public Health Foundation of India, New Delhi, India; 26Center for Biotechnology and Fine Chemistry, Associate Laboratory, Faculty of Biotechnology, Catholic University of Portugal, Porto, Portugal; 27Bielefeld University, Bielefeld, Germany; 28National Heart, Lung, and Blood Institute, Framingham, MA; 29University Medical Center Groningen, Groningen, Netherlands; 30University of Massachusetts Boston, Boston, MA; 31School of Medicine and 32Departments of Epidemiology and Medicine, University of Alabama at Birmingham, Birmingham, AL; 33Hamdan Bin Mohammed Smart University, Dubai, United Arab Emirates; 34Department of Epidemiology and Health Promotion, Institute for Health Promotion, Graduate School of Public Health, Yonsei University, Seoul, South Korea; 35George Institute for Global Health, New Delhi, India; 36University of Oxford, Oxford, England, United Kingdom; 37Department of Ocular Epidemiology and Visual Health, Institute of Ophthalmology Conde de Valencia, Mexico City, Mexico; 38General Directorate of Epidemiology, Ministry of Health, Mexico City, Mexico; 39Department of Ophthalmology, Medical Faculty Mannheim, Ruprecht-Karls-University Heidelberg, Mannheim, Germany; 40South African Medical Research Council, Cape Town, South Africa; 41Department of Medicine, University of Cape Town, Cape Town, South Africa; 42Jordun University of Science and Technology, Irbid, Jordan; 43College of Medicine, Seoul National University, Seoul, South Korea; 44Southern University College, Skudai, Malaysia; 45Department of Ophthalmology and Visual Sciences and 46Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, WI; 47Department of Preventive Cardiology, National Cerebral and Cardiovascular Center, Suita, Japan; 48Division of Cardiology, Brown University, Providence, Rhode Island; 49Division of Nephrology, Tufts Medical Center, Boston, MA; 50General Internal Medicine, San Francisco Veterans Affairs Medical Center, San Francisco, CA; 51Mansoura Faculty of Medicine, Mansoura, Egypt; 52United Nations Population Fund, Lima, Peru; 53Tohoku University, Sendai, Japan; 54Osaka Medical Center for Cancer and Cardiovascular Diseases Prevention, Osaka, Japan; 55Department of Social and Environmental Medicine, Osaka University Graduate School of Medicine, Osaka, Japan; 56IS-Fundacion Jimenez Diaz-UMA, Madrid, Spain; 57Nephrology, Monash Medical Centre, Melbourne, Victoria, Australia; 58Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia; 59Ministry of Health, Jeddah, Saudi Arabia; 60Azienda Socio-Sanitaria Territoriale, Papa Giovanni XXIII, Bergamo, Italy; 61Department of Biomedical and Clinical Sciences "L. Sacco", University of Milan, Milan, Italy; 62Institute of Medicine and Medical Biometry, Ulm University, Ulm, Germany; 63Marshall University, 64
Health Outcomes of Reduced GFR